In our study, SLC39A4 exhibited the highest HR value in Cox regression and LASSO regression analysis, and survival analysis revealed that patients with high SLC39A4 expression had considerably worse prognosis, suggesting that SLC39A4 might be a biomarker of ICC progression, and could represent a potential therapeutic target. This evidence concerns the gene SLC39A4 and intrahepatic cholangiocarcinoma.